MétaCan
Menu
Back to cohort
Record W4409222014 · doi:10.1161/atvb.39.suppl_1.407

Abstract 407: Apabetalone (RVX-208) Inhibits Key Pro-Atherogenic Mediators and Pathways in Diabetes and Inflammatory Conditions; <i>in vitro</i> and in Patients

2019· article· en· W4409222014 on OpenAlexaff
Laura Tsujikawa, Brooke D. Rakai, Shovon Das, Christopher Halliday, Stephanie C. Stotz, Michael Sweeney, Jan O. Johansson, Norman C. Wong, Ewelina Kulikowski

Bibliographic record

VenueArteriosclerosis Thrombosis and Vascular Biology · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicAtherosclerosis and Cardiovascular Diseases
Canadian institutionsResverlogix (Canada)
Fundersnot available
KeywordsDiabetes mellitusIn vitroMedicineInflammationInternal medicineEndocrinologyChemistryBiochemistry

Abstract

fetched live from OpenAlex

Apabetalone (RVX-208) is a small molecule bromodomain & extraterminal (BET) protein inhibitor that targets the second bromodomain (BD2) within BET proteins. In phase 2 trials, apabetalone treatment reduced relative risk of MACE events by 57% in patients with cardiovascular disease (CVD) and type II diabetes (T2DM). In both CVD and T2DM, elevated circulating glucose, inflammatory mediators, and cell surface adhesion molecules drive vascular inflammation (VI), resulting in the recruitment, adhesion, and infiltration of leukocytes to the atherosclerotic plaque. Continuous inflammation promotes cytokine production, immune cell infiltration, and plaque rupture, which accounts for 67% of fatal myocardial infarctions (MIs) and sudden cardiac deaths. Here we show in vitro that TNFα and high glucose treatment induced significant adhesion of THP-1 monocytes to endothelial cells, an outcome inhibited by apabetalone treatment. Apabetalone suppressed the transcription of critical drivers of pro-inflammatory signaling ( RELA ), immune cell activation and recruitment ( MCP-1 ), and plaque rupture ( IL-8 ) in endothelial cells. Ingenuity® Pathway Analysis (IPA®), GSEA, and GO analysis of human umbilical vein endothelial cell (HUVEC) gene expression data predicted that apabetalone would inhibit pro-atherogenic pathways, gene sets, and upstream regulators. These include cytokine and chemokine signalling, immune and inflammatory response, Toll-Like Receptor (TLR) signalling, and TNFα signalling. In addition, IPA® disease and biological function analysis predicted inhibition of immune cell recruitment and activation by apabetalone. These in vitro effects are consistent with plasma proteomic results (SOMAscan®) from apabetalone-treated CVD T2DM patients, which demonstrated inhibitory effects on TNFα signalling, acute phase response, intrinsic prothrombin activation, leukocyte extravasation signalling and coagulation. Amelioration of diabetes and inflammation driven atherogenesis by apabetalone treatment likely contributes to the reduction in MACE observed in phase 2. The ongoing phase 3 post-ACS clinical trial in T2DM patients, BETonMACE, is investigating the effect of apabetalone on MACE reduction and will report in 2019.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.203
Teacher spread0.194 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueArteriosclerosis Thrombosis and Vascular BiologySame topicAtherosclerosis and Cardiovascular DiseasesFrench-language works237,207